PRT062607: Development discontinued

Biogen Idec disclosed in its 3Q12 earnings conference call that it and partner Portola discontinued development of PRT062607 to treat RA because the compound "did not meet the stringent target product profile to be competitive." Biogen Idec said the partners will continue to conduct exploratory research of PRT062607 to treat allergic asthma, as well as develop SYK-selective backup compounds in autoimmune and inflammatory diseases. ...